%0 Journal Article
%T Segundas l¨ªneas en c¨¢ncer de ovario: £¿hay un est¨¢ndar?
%A Gonz¨¢lez Mart¨ªn
%A A.
%A Murcia
%A M.
%A Vaz
%A M. A.
%A L¨®pez Miranda
%A E.
%A L¨®pez Garc¨ªa
%A M.
%J Oncolog¨ªa (Barcelona)
%D 2007
%I Scientific Electronic Library Online
%R 10.4321/S0378-48352007000100002
%X recurrent ovarian carcinoma is usually incurable and palliative chemotherapy is the treatment of choice. in those patients considered as platinum-sensitive (with a platinum-free interval over 6 months) we have enough evidence to recommend carboplatin-based combination chemotherapy, due to the impact in survival observed in clinical trials comparing carboplatin monotherapy versus combination chemotherapy. on the other band, in those patient with progression to a platinum based chemotherapy (refractory) or with relapse in a period of less than 6 months (resistant), sequential monotherapy with active drugs in the second line is the recommended approach. the absence of a standard drug in this context makes that the choice should be based on toxicity criteria, quality of life and the preference of the patient.
%K recurrent ovarian cancer
%K second line
%K platinum sensitive
%K platinum resistant.
%U http://scielo.isciii.es/scielo.php?script=sci_abstract&pid=S0378-48352007000100002&lng=en&nrm=iso&tlng=en